Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20741308 | 1.00 | ADRA2A (0.35) | ADRA2AADRA2BADRA2CPLAUS1PR3 | |
| SCHEMBL10670778 | 0.80 | ADRA2A (0.33) | ADRA2AADRA2BADRA2CPLAUS1PR3 | |
| SCHEMBL9625236 | 0.77 | ESR1 (0.42) | — | |
| SCHEMBL1853872 | 0.77 | ADRA2A (0.35) | ADRA2AADRA2BADRA2CPLAUS1PR3 | |
| SCHEMBL10321351 | 0.74 | ADRB2 (0.39) | ADRA2AADRA2BADRA2CPLAUS1PR3 | |
| SCHEMBL10321352 | 0.74 | ADRB2 (0.39) | ADRA2AADRA2BADRA2CPLAUS1PR3 | |
| SCHEMBL2563540 | 0.74 | ALDH1A1 (0.35) | L3MBTL1FDPS | |
| SCHEMBL15332425 | 0.74 | ALDH1A1 (0.35) | L3MBTL1FDPS | |
| SCHEMBL4337075 | 0.74 | ADRB2 (0.46) | ADRA2AADRA2BADRA2CPLAUS1PR3 | |
| SCHEMBL4323766 | 0.74 | ADRB2 (0.46) | ADRA2AADRA2BADRA2CPLAUS1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356344-B1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LTD (GB) | 2022-11-16 | — | — | EP | disclosed |
| CN-108473464-B | Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity | 阿斯泰克斯治疗有限公司 | 2022-08-23 | — | — | CN | disclosed |
| US-20220106287-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2022-04-07 | — | — | US | disclosed |
| US-11261171-B1 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2022-03-01 | — | — | US | disclosed |
| US-20190055215-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| US-20190055215-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106287-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | ADRA2A 3963/4885ADRA2B 3931/4885ADRA2C 3919/4885 |
| US-20190055215-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | ADRA2A 3963/4885ADRA2B 3931/4885ADRA2C 3919/4885 |
| US-11261171-B1 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | ADRA2A 3963/4885ADRA2B 3931/4885ADRA2C 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.